GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
Status:
RECRUITING
Trial end date:
2027-12-30
Target enrollment:
Participant gender:
Summary
This is a prospective clinical study to evaluate the safety and efficacy of GVM±R in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).
Phase:
PHASE2
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Collaborators:
Affiliated Cancer Hospital & Institute of Guangzhou Medical University Beijing Tongren Hospital Chengdu Shangjin Nanfu Hospital China-Japan Friendship Hospital First Affiliated Hospital of Harbin Medical University First Hospital of China Medical University Hebei Medical University Fourth Hospital Peking University Third Hospital People's Hospital of Zhengzhou University Shengjing Hospital The Affiliated Ganzhou Hospital of Nanchang University The First Affiliated Hospital of Bengbu Medical University The First Affiliated Hospital of Dalian Medical University The First Affiliated Hospital of Nanchang University The First Hospital of Jilin University The Second Affiliated Hospital of Harbin Medical University The Second Affiliated Hospital of Kunming Medical University Xuanwu Hospital, Beijing